Paradigm shift in NMDA receptor antagonist drug development: Molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders

Journal of Alzheimer's Disease

Volumn 6, Issue SUPPL., 2004, Pages

  Lipton, Stuart A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DIZOCILPINE; DONEPEZIL; GLUTAMIC ACID; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; NITROMEMANTINE DERIVATIVE; UNCLASSIFIED DRUG;

AGITATION; ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG MECHANISM; EXCITOTOXICITY; HUMAN; MOLECULAR MECHANICS; MULTIINFARCT DEMENTIA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RESTLESSNESS; SIDE EFFECT;

EID: 13444291406     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/jad-2004-6s610     Document Type: Article

References (72)

1. S.A. Lipton and P.A. Rosenberg, Mechanisms of disease: Excitatory amino acids as a final common pathway for neurologic disorders, N Engl J Med 330 (1994), 613-622.
2. S.A. Lipton and P. Nicotera, Calcium, free radicals and excitotoxins in neuronal apoptosis, Cell Calcium 23 (1998), 165-171.
3. J.A. Kemp and R.M. McKernan, NMDA receptor pathways as drug targets, Nat Neurosci 5(Suppl) (2002), 1039-1042.
4. K.R. Lees, K. Asplund, A. Carolei, S.M. Davis, H.C. Diener, M. Kaste, J.M. Orgogozo and J. Whitehead, Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial, GAIN International Investigators, Lancet 355 (2000), 1949-1954.
5. R.L. Sacco, J.T. DeRosa, B.C. Haley, Jr., B. Levin, P. Ordronneau, S.J. Phillips, T. Rundek, R.G. Snipes and J.L. Thompson, Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial, Jama 285 (2001), 1719-1728.
6. J.A. Kemp, J.N. Kew and R. Gill, in: Handbook of Experimental Pharmacology, P. Jonas and H. Monyer, eds, Springer, Berlin 101 (1999), 495-527.
7. M. Seif el Nasr, B. Peruche, C. Rossberg, H.D. Mennel and J. Krieglstein, Neuroprotective effect of memantine demonstrated in vivo and in vitro, Eur J Pharmacol 185 (1990), 19-24.
8. S.A. Lipton, Prospects for clinically tolerated NMDA antagonists: open-channel blockers and alternative redox states of nitric oxide, Trends Neurosci 16 (1993), 527-532.
9. H.-S.V. Chen and S.A. Lipton, Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism, J Physiol (Lond) 499 (1997), 27-46.
10. H.-S.V. Chen, J.W. Pellegrini, S.K. Aggarwal, S.Z. Lei, S. Warach, F.E. Jensen and S.A. Lipton, Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity, J Neurosci 12 (1992), 4427-4436.
11. H.-S.V. Chen, Y.F. Wang, P.V. Rayudu, P. Edgecomb, J.C. Neill, M.M. Segal, S.A. Lipton and F.E. Jensen, Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation, Neuroscience 86 (1998), 1121-1132.
12. B. Reisberg, R. Doody, A. Stoffler, F. Schmitt, S. Ferris and H.J. Mobius, Memantine in moderate-to-severe Alzheimer's disease, N Engl J Med 348 (2003), 1333-1341.
13. J.M. Orgogozo, A.S. Rigaud, A. Stoffler, H.J. Mobius and F. Forette, Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomzed, placebo-controlled trial (MMM 300), Stroke 33 (2002), 1834-1839.
14. D.R. Lucas and J.P. Newhouse, The toxic effect of sodium L-glutamate on the inner layers of the retina, Ama Arch Opthalmol 58 (1957), 193-201.
15. J.W. Olney, Glutamate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion, J Neuropathol Exp Neurol 28 (1969), 455-474.
16. J.W. Olney and O.L. Ho, . Brain damage in infant mice following oral intake of glutamate, aspartate or cysteine, Nature 227 (1970), 609-611.
17. S.A. Lipton, Molecular mechanisms of trauma-induced neuronal degeneration, Curr Opin Neural Neurosurg 6 (1993), 588-596.
18. E. Bonfoco, D. Krainc, M. Ankarcrona, P. Nicotera and S.A. Lipton, Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures, Proc Natl Acad Sci USA 92 (1995), 7162-7166.
19. E.B. Dreyer, D. Zhang and S.A. Lipton, Transcriptional or translational inhibition blocks low dose NMDA-mediated cell death, Neuroreport 6 (1995), 942-944.
20. H.A. Quigley, R.W. Nickells, L.A. Kerrigan, M.E. Pease, D.J. Thibault, and D.J. Zack, Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis, Invest Ophthalmol Vis Sci 36 (1995), 774-786.
21. C.K. Vorwerk, S.A. Lipton, D. Zurakowski, B.T. Hyman, B.A. Sabel and E.B. Dreyer, Chronic low-dose glutamate is toxic to retinal ganglion cells, Toxicity blocked by memantine, Invest Ophthalmol Vis Sci 37 (1996), 1618-1624.
22. E.B. Dreyer and C.L. Grosskreutz, Excitatory mechanisms in retinal ganglion cell death in primary open angle glaucoma (POAG), Clin Neurosci 4 (1997), 270-273.
23. E.B. Dreyer and S.A. Lipton, New perspectives on glaucoma, JAMA 281 (1999), 306-308.
24. R. Naskar, C.K. Vorwerk and E.B. Dreyer, Saving the nerve from glaucoma: memantine to caspaces, Semin Ophthalmol 14 (1999), 152-158.
25. 2+ block at the N-methyl-D-aspartate receptor underlies receptor activation during inhibition of neuronal metabolism, J Neurochem 59 (1992), 1211-1220.
26. M.A. Rogawski and G.L. Wenk, The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease, CNS Drug Rev 9 (2003), 275-308.
27. D.J. Selkoe, Alzheimer's disease: genes, proteins, and therapy, Physiol Rev 81 (2001), 741-766.
28. J. Wu, R. Anwyl and M.J. Rowan, beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro, Eur J Pharmacol 284 (1995), R1-R3.
29. M.P. Mattson, B. Cheng, D. Davis, K. Bryant, I. Lieberburg and R.E. Rydel, beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity, J Neurosci 12 (1992), 376-389.
30. J.Y. Koh, L.L. Yang and C.W. Cotman, Beta-amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage, Brain Res 533 (1990), 315-320.
31. R. Topper, J. Gehrmann, R. Banati, M. Schwarz, F. Block, J. Noth and G.W. Kreutzberg, Rapid appearance of beta-amyloid precursor protein immunoreactivity in glial cells following excitotoxic brain injury, Acta Neuropathol (Berl) 89 (1995), 23-28.
32. T. Harkany, I. Abraham, W. Timmerman, G. Laskay, B. Toth, M. Sasvari, C. Konya, J.B. Sebens, J. Korf, C. Nyakas, M. Zarandi, K. Soos, B. Penke and P.G. Luiten, beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis, Eur J Neurosci 12 (2000), 2735-2745.
33. P. Couratier, M. Lesort, P. Sindou, F. Esclaire, C. Yardin and J. Hugon, Modifications of neuronal phosphorylated tau immunoreactivity induced by NMDA toxicity, Mol Chem Neuropathol 27 (1996), 259-273.
34. J.J. Miguel-Hidalgo, X.A. Alvarez, R. Cacabelos and G. Quack, Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40), Brain Res 958 (2002), 210-221.
35. H. Tanila, R. Minkevicine and P. Banjeree, Behavioral effects of subchronic memantine treatment in APP/PS1 double mutant mice modeling Alzheimer's disease, J Neurochem 85(Suppl 1) (2003), 42.
36. K. Iqbal and L. Li, Sengupta A and Grundke-Iqbal I. Memantine restores okadaic acid-induced changes in protein phosphatase-2A, CAMKII and tau hyperphosphorylation in rat, J Neurochem 85(Suppl 1) (2003), 42.
37. V.L. Dawson, T.M. Dawson, E.D. London, D.S. Bredt and S.H. Snyder, Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures, Proc Natl Acad Sci USA 88 (1991), 6368-6371.
38. V.L. Dawson, T.M. Dawson, D.A. Bartley, G.R. Uhl and S.H. Snyder, Mechanisms of nitric oxide-mediated neurotoxicity in primary brain cultures, J Neurosci 13 (1993), 2651-2661.
39. S.A. Lipton, Y.B. Choi, Z.H. Pan, S.Z. Lei, H.-S.V. Chen, N.J. Sucher, J. Loscalzo, D.J. Singel and J.S. Stamler, A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364 (1993), 626-632.
40. L. Tenneti, D.M. D'Emilia, C.M. Troy and S.A. Lipton, Role of caspases in N-methyl-D-aspartate-induced apoptosis in cerebrocortical neurons, J Neurochem 71 (1998), 946-959.
41. H.Y. Yun, M. Gonzalez-Zulueta, V.L. Dawson and T.M. Dawson, Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras, Proc Natl Acad Sci USA 95 (1998), 5773-5778.
42. S.L. Budd, L. Tenneti, T. Lishnak and S.A. Lipton, Mitochondrial and extramitochondrial apoptotic signaling pathways in cerebrocortical neurons, Proc Natl Acad Sci USA 97 (2000), 6161-6166.
43. S. Okamoto, Z. Li, C. Ju, M.N. Scholzke, E. Mathews, J. Cui, G.S. Salvesen, E. Bossy-Wetzel and S.A. Lipton, Dominant-interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis, Proc Natl Acad Sci USA 99 (2002), 3974-3979.
44. J.W. Johnson and P. Ascher, Glycine potentiates the NMDA response in cultured mouse brain neurons, Nature 325 (1987), 529-531.
45. C.J. McBain and M.L. Mayer, N-methyl-D-aspartic acid receptor structure and function, Physiol Rev 74 (1994), 723-760.
46. S.A. Lipton, Y.B. Choi, H. Takahashi, D. Zhang, W. Li, A. Godzik and L.A. Bankston, Cysteine regulation of protein function-as exemplified by NMDA-receptor modulation, Trends Neurosci 25 (2002), 474-480.
47. W.J. Koroshetz and M.A. Moskowitz, Emerging treatments for stroke in humans. Trends Pharmacol Sci 17 (1996), 227-233.
48. S.L. Hickenbottom and J. Grotta, Neuroprotective therapy, Semin Neurol 18 (1998), 485-492.
49. H.L. Lutsep and W.M. Clark, Neuroprotection in acute ischaemic stroke. Current status and future potential, Drugs RD 1 (1999), 3-8.
50. M.A. Rogawski, Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents-toward an understanding of their favorable tolerability, Amino Acids 19 (2000), 133-149.
51. G.C. Palmer, Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies, Curr Drug Targets 2 (2001), 241-271.
52. H.-S.V. Chen, M. Rastogi and S.A. Lipton, Q/R/N site mutations in the M2 region of NMDAR1/NMDAR2A receptors reveal a non-specific site for memantine action, Soc Neurosci Abstr 24 (1998), 342.
53. J. Bormann, Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels, Eur J Pharmacol 166 (1989), 591-592.
54. T.A. Blanpied, F.A. Boeckman, E. Aizenman and J.W. Johnson, Trapping channel block of NMDA-activated responses by amantadine and memantine, J Neurophysiol 77 (1997), 309-323.
55. A.I. Sobolevsky, S.G. Koshelev and B.I. Khodorov, Interaction of memantine and amantadine with agonist-unbound NMDA-receptor channels in acutely isolated rat hippocampal neurons, J Physiol (Lond) 512 (1998), 47-60.
56. G. Rammes, R. Rupprecht, U. Ferrari, W. Zieglgansberger and C.G. Parsons, The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkylcyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner, Neurosci Lett 306 (2001), 81-84.
57. G. Reiser, F.J. Binmoller and R. Koch, Memantine (1-amino-3,5- dimethyladamantane) blocks the serotonin-induced depolarization response in a neuronal cell line, Brain Res 443 (1988), 338-344.
58. C.G. Parsons, W. Danysz and G. Quack, Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data, Neuropharmacology 38 (1999), 735-767.
59. S.A. Lipton, Memantine prevents HIV coat protein-induced neuronal injury in vitro, Neurology 42 (1992), 1403-1405.
60. J.W. Pellegrini and S.A. Lipton, Delayed administration of memantine prevents N-methyl-D-aspartate receptor-mediated neurotoxicity, Ann Neurol 33 (1993), 403-407.
61. N.J. Sucher, S.A. Lipton and E.B. Dreyer, Molecular basis of glutamate toxicity in retinal ganglion cells, Vision Res 37 (1997), 3483-3493.
62. N.N. Osborne, Memantine reduces alterations to the mammalian retina, in situ, induced by ischemia, Vis Neurosci 16 (1999), 45-52.
63. B. Winblad and N. Poritis, Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine), Int J Geriatr Psychiatry 14 (1999), 135-146.
64. S.A. Lipton and Y.F. Wang, NO-related species can protect from focal cerebral ischemia/reperfusion, in: Pharmacology of Cerebral Ischemia, J. Krieglstein and H. Oberpichler-Schwenk, eds, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 1996, pp. 183-191.
65. D. Zurakowski, C.K. Vorwerk, M. Gorla, A.J. Kanellopoulos, N. Chaturvedi, C.L. Grosskreutz, S.A. Lipton and E.B. Dreyer, Nitrate therapy may retard glaucomatous optic neuropathy, perhaps through modulation of glutamate receptors, Vision Res 38 (1998), 1489-1494.
66. S.A. Lipton, P.V. Rayudu, Y.B. Choi, N.J. Sucher and H.-S.V. Chen, Redox modulation of the NMDA receptor by NO-related species, in: Progr Brain Res, V. Mize, T.M. Dawson, M. Dawson and M. Friedlander, eds, Elsevier, Amsterdam 118 (1998), 73-82.
67. Y.B. Choi, L. Tenneti, D.A. Le, J. Ortiz, G. Bai, H.-S.V. Chen and S.A. Lipton, Molecular basis of NMDA receptor-coupled ion channel modulation by S-nitrosylation, Nat Neurosci 3 (2000), 15-21.
68. M. Ankarcrona, J.M. Dypbukt, E. Bonfoco, B. Zhivotovsky, S. Orrenius, S.A. Lipton and P. Nicotera, Glutamate-induced neuronal death: a succession of necrosis or apoptosis depending on mitochondrial function, Neuron 15 (1995), 961-973.
69. D.A. Le and S.A. Lipton, Potential and current use of N-methyl-D-aspartate (NMDA) receptor antagonists in diseases of aging, Drugs Aging 18 (2001), 717-724.
70. S.A. Lipton, Concepts: Turning down but not off-Neuroprotection requires a paradigm shift in drug development, Nature 428 (2004), 473.
71. S.-I. Okamoto, Z. Li, C. Ju, M.N. Schölzke, E. Matthews, J. Cui, G.S. Salvesen, E. Bossy-Wetzel and A. Lipton, Dominant interfering forms of MEF2 generated by caspase cleavage contribute to NMDA-induced neuronal apoptosis, Proc Natl Acad Sci USA 99 (2002), 3974-3979.
72. P.N. Tariot, M.R. Farlow, G.T. Grossberg, S.M. Graham, S. McDonald and I. Gergel, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial, JAMA 291 (2004), 317-324.